Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 11/20 | 0.38 |
| ▸ | JAK1 | P23458 | 11/20 | 0.38 |
| ▸ | JAK3 | P52333 | 11/20 | 0.38 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 5/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7942597 | 0.87 | CCNT1 (0.40) | CCNT1CDK9CAMKK1CAMKK2JAK2 | |
| SCHEMBL7954528 | 0.83 | CCNT1 (0.41) | CCNT1CDK9JAK2JAK1JAK3 | |
| SCHEMBL8043844 | 0.83 | GSK3A (0.54) | CCNT1CDK9CAMKK1CAMKK2CDK2 | |
| SCHEMBL13099806 | 0.81 | KCNQ3 (0.43) | CAMKK1CAMKK2JAK2JAK1JAK3 | |
| SCHEMBL13099782 | 0.80 | CCNT1 (0.39) | CCNT1CDK9JAK2JAK1JAK3 | |
| SCHEMBL8043843 | 0.79 | GSK3A (0.58) | CDK2ADORA2AADORA1 | |
| SCHEMBL8043772 | 0.77 | KDM4E (0.38) | JAK2JAK1JAK3IGF1RKCNH2 | |
| SCHEMBL7950686 | 0.73 | KDM4E (0.38) | JAK2JAK1JAK3IGF1RKCNH2 | |
| SCHEMBL8049613 | 0.71 | ATM (0.42) | JAK2JAK1JAK3EPHB3IGF1R | |
| SCHEMBL7950685 | 0.71 | ALDH1A1 (0.43) | JAK2JAK1JAK3EPHB3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | CCNT1 2221/4885CDK9 87/4885CAMKK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.